Loading data for GRCE — first visit, this takes a few seconds.
Grace Therapeutics, Inc. (GRCE)
NasdaqCM: GRCE
· 即時價格 · USD
2.22
-0.04 (-1.77%)
收盤價： Sep 11, 2026, 8:00 PM
2.22
+0.00%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Grace Therapeutics, Inc.（GRCE）股價、分析與資料
無可用資料
| 買價 | 1.65 |
| 市值 | 46.7M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -20.2M |
| 0.44 | |
| -1.17 | |
| n/a | |
| -4.8 | |
| P/B (ttm) | 0.75 |
| P/S (ttm) | 0.00 |
| 財報日期 | Jun 20, 2025 |
| 賣價 | 2.89 |
| 成交量 | 715,952 |
| 20 日平均成交量 | 220,788 |
| 開盤價 | 2.29 |
| 前收盤價 | 2.26 |
| 當日區間 | 2.21 - 2.46 |
| 52 週範圍 | 1.79 - 5.18 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-form...
完整的公司簡介財報驚奇
Grace Therapeutics 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.18 低於預期 0.00, 年增 37.93% 成長.
